Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$204.76 USD

204.76
878,984

-0.06 (-0.03%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific

The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy Right Now

Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.

Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Mark Vickery headshot

Top Research Reports for Chubb, Las Vegas Sands & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Chubb (CB), Las Vegas Sands (LVS) and Biogen (BIIB).

Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid

Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.

Kinjel Shah headshot

5 Low Price-to-Book Value Stocks for Great Returns

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?

Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.

PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y

PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on String of Q1 Earnings Beats

Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex

The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex

Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates

Key highlights of the past week are earnings releases by most leading biotech entities.

What's in the Cards for Sunesis (SNSS) This Earnings Season?

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy Right Now

Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...

Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1

Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.

Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

Biogen (BIIB) Q1 Earnings & Sales Beat Estimates

Biogen (BIIB) beat estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

What's in Store for Celgene Corporation (CELG) Q1 Earnings?

Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.

Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?

While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.

Will Bristol-Myers (BMY) Disappoint This Earnings Season?

Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.

Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs

Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.

Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.

Biogen (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen (BIIB) closed the most recent trading day at $237.58, moving -0.9% from the previous trading session.

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Celgene Gets Positive CHMP Nod for Revlimid Label Expansion

Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.